



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BIOMARK ANNOUNCES INTENTION TO REFILE RESTATED AND AMENDED MARCH 31ST, 2016 AUDITED ANNUAL FINANCIAL STATEMENTS AND MD&A

Vancouver, British Columbia – (September 26, 2016) – BioMark Diagnostics Inc. ("BioMark" or the "Company") (CSE: BUX, OTCQB: BMKDF; FSE: 20B), announces that it intends to file amended and restated audited financial statements and a revised management discussion and analysis ("MD&A") for the year ended March 31, 2016. (collectively, the "**Restatements**").

BioMark has identified certain errors that were made on the Company's cash flow statements. The Company intends to correct those errors and refile its annual audited financial statements along with its MD&A for the year ending March 31, 2016. The correction of the errors will result in a decrease of \$649,075 in cash used in operating activities and a corresponding decrease in cash provided by financing activities. Cash used in operating activities will decrease from \$960,008 to \$310,933 and cash provided by financing activities will decrease from \$777,905 to \$128,830. The errors were a result of misclassification of certain amounts between cash used in operating activities and cash provided by financing activities and some non-cash items were incorrectly recorded. In addition, the Company will amend and restate its MD&A with regard to the errors made in its statement of cash flows and will make other minor changes.

About BioMark Diagnostics Inc.

BioMark Diagnostics is developing proprietary, non-invasive, and accurate cancer diagnostic solutions, which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark Diagnostics is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

Company Contact

Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
604-282-6567
info@biomarkdiagnostics.com

Forward-Looking Information

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking

information is based on reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.